Modality
siRNA
MOA
TROP-2 ADC
Target
IL-13
Pathway
Wnt
MDSHS
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Jun 2027
Phase 1Current
NCT04679907
36 pts·HS
2019-02→2027-06·Active
36 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-251.2y awayInterim· HS
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Active
Catalysts
Interim
2027-06-25 · 1.2y away
HS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04679907 | Phase 1 | HS | Active | 36 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |